Another step forward: India releases updated biosimilar guidelines
01 August 2016
Following feedback from industry, health policy experts and the public, India recently updated its draft guidelines for biosimilars, narrowing down the conditions for waivers of late-stage trials and expanding some testing criteria. "The revised guidelines have considered some stakeholder input, relative to the conduct of clinical trials and safety/efficacy studies," Ranjana Smatacek, former director general of the Organisation of Pharmaceutical producers of India (OPPI), told BioWorld Asia.
Old patients with HIV are the new group with unique needs
01 August 2016
n the early days of the AIDS epidemic, the life expectancy for those diagnosed with HIV was two years from the time of diagnosis. In the era of antiretroviral therapy, Johnson & Johnson's chief scientific officer, Paul Stoffels, told the audience at the 2016 International AIDS Conference this week, "people can see their kids and their grandkids grow up, if therapy is done well."
Work begins on plan to prioritize U.K. life sciences post-Brexit
29 July 2016
Work starts Monday on drawing up a life sciences transition program that the industry intends to present to government on Sept. 6 as a blueprint for negotiating the U.K.'s exit from the EU on favorable terms for the sector. The intention is to spend the next six weeks scoping the risks that need to be addressed and identifying opportunities to make the U.K. domestic landscape as strong and attractive as possible in the post-Brexit future.
New tools for assessing drug value haven’t caught on with payers — yet
29 July 2016
As prices for prescription drugs keep rising, several organizations have developed different ways to assess the value of new medicines based on such attributes as cost, quality of life, and effectiveness. But a new survey finds that even as health plans continue to criticize drug prices, they have not yet embraced these new tools.
MIT researchers develop hydrogel patch to deliver cancer combo
29 July 2016
Researchers at MIT have published a paper about an adhesive hydrogel patch that could be used in the treatment of colorectal tumors after surgery.
New medication shows promise against liver fibrosis in animal studies
28 July 2016
A new drug developed by scientists at the National Institutes of Health limits the progression of liver fibrosis in mice, a hopeful advance against a condition for which there is no current treatment and that often leads to serious liver disease in people with chronic alcoholism and other common diseases.
Pharma trade group says price gougers are outliers, but then accepts two more
28 July 2016
or months, the trade group representing big drug makers has argued that Valeant Pharmaceuticals and Turing Pharmaceuticals, which was once run by Martin Shkreli, were outliers for brazen pricing practices that outraged Americans.
U.S. public opinion on the future use of gene editing
28 July 2016
The potential genetic modification of humans and its ramifications have long been debated, but a recent scientific breakthrough in gene editing – a technique known as CRISPR – has raised the urgency of this conversation. In March and April of 2015, two separate groups of scientists published essays urging the scientific community to impose limits on genomic engineering, and the National Academies of Sciences, working in cooperation with the United Kingdom’s Royal Society and the Chinese Academy of Sciences, convened an international summit to discuss the science and policy of human gene editing.
Syndax Appoints Leading Experts to Scientific Advisory Board (SAB)
27 July 2016
Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat in multiple cancer indications, today announced that it has entered into an exclusive worldwide license agreement with UCB for UCB6352, an IND-ready anti-CSF-1R monoclonal antibody, which is expected to begin clinical trials in 2016.
China poised to make CRISPR history with first in vivo trial
27 July 2016
A research team led by You Lu has received ethics clearance for what is expected to be the first in vivo trial using CRISPR gene editing technology. The Phase I trial is slated to be conducted at the West China Hospital.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Russia has expanded the mandatory health insurance program for 2024-2026
29 March 2024
Russian scientists have developed new TB vaccines for both injection and nasal administration.
29 March 2024
The overall mortality rate of the population in Russia decreased by 7% in 2023
28 March 2024
Russia to collaborate with Hungary and Serbia in nuclear medicine
28 March 2024